Figure 1.
Subsite-specific hazard ratios (HR), solid lines, with 95% confidence intervals (CI), dashed lines, of cardia (C16.0), proximal (C16.1–C16.2), distal (C16.3–C16.4) and unspecified (C16.5–C16.6, C16.8–C16.9) site of stomach cancer with 1+ prescriptions of histamine type-2 receptor antagonists (H2RA) and proton-pump inhibitors (PPI), time since first exposure, years 1995–2011.